Axsome Therapeutics, Inc…announced that the U.S. Food and Drug Administration (FDA) has accepted for ﬁling the Company&#39;s New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy.

reboxetine (AXS-12) - Axsome Therap

Jul 15, 2026